Selexipag could improve functional status associated with chronic obstructive pulmonary disease (COPD)among patients with pulmonary hypertension (PH), according to findings from a new study.
In trial data presented at the Heart Failure Society of America (HFSA) 2019 Scientific Session in Philadelphia, PA, a team of investigators from the University of Nebraska Medical Center reported findings showing the prostacyclin-targeting therapy benefits comorbid COPD in patients with out-of-proportion PH.
Led by Sherif TH Abuserewa, MD, the team sought the benefit of selexipag in patients who make up less than 5% of the PH population. Out-of-proportion PH is associated with an “intrinsic pulmonary vascular pathology,” they noted—one different from the mild PH which affects a majority of patients with COPD (mean pulmonary artery pressure [mPAP]
